Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue
Product sales	$ 2,701,142	$ 1,236,349
Laboratory services	120,476	478,909
Collaborations revenue	336,102	2,411,120
Total revenue	3,157,720	4,126,378
Operating expenses
Costs of products sold	1,179,771	425,541
Costs of services	367,802	526,196
Research and development	6,002,941	4,368,302
General and administrative	5,834,642	2,312,935
Sales and marketing	4,305,444	2,058,085
Transaction expenses	526,283	0
Total operating expenses	18,216,883	9,691,059
Operating loss	(15,059,163)	(5,564,681)
Other income (expense)
Interest and other income	26,657	156
Interest expense	(1,801,320)	(111,345)
Change in fair value of derivative financial instruments and other	(647,342)	4,400
Total other income (expense)	(2,422,005)	(106,789)
Loss before income taxes	(17,481,168)	(5,671,470)
Income tax benefit	(129,095)	0
Net loss	(17,352,073)	(5,671,470)
Accretion of Series A preferred stock	(243,762)	(627,133)
Net loss available to common stockholders	$ (17,595,835)	$ (6,298,603)
Net loss per common share - basic and diluted (in dollars per share)	$ (2.20)	$ (16.25)
Weighted average shares outstanding - basic and diluted (in shares)	7,980,995	387,590
Net loss	$ (17,352,073)	$ (5,671,470)
Other comprehensive loss - foreign currency translation	(1,059)	0
Comprehensive loss	$ (17,353,132)	$ (5,671,470)